- |||||||||| RV-1521 / Sirnaomics
RV-1521: A broad-spectrum mRNA vaccine targeting KRAS mutations in cancer (Section 24; Poster Board No: 5) - Mar 25, 2025 - Abstract #AACR2025AACR_9032;
While KRAS G12C inhibitors, such as sotorasib and adagrasib, have made significant progress, their mutation-specificity excludes up to 85% of KRAS-mutant cancers, including those with G12D, G12V, and G13D mutations...Its ability to synergize with anti-PD-1 therapy and elicit a robust, multi-faceted antitumor immune response positions it as a promising strategy for treating KRAS-driven cancers. Ongoing studies will evaluate its safety and adaptability across diverse microenvironments and patient populations.
|
